Results from a clinical trial investigating a new T cell receptor (TCR) therapy that uses a person's own immune system to recognize and destroy cancer cells demonstrated a clinical response in 80 percent
of multiple myeloma patients with advanced disease after undergoing autologous stem cell transplants (ASCT).
4:05 pm: Deborah Brooks of The Michael J. Fox Foundation for Parkinson's Research; Kathy Giusti
of the Multiple Myeloma Research Foundation & Consortium; Sean Lane of Crosschx; Claudia Williams of the White House Office of Science and Technology Policy; Rik Kirkland, of McKinsey & Co..
Eppie died
of multiple myeloma at age 83, while Pauline lived to be 94 before succumbing to Alzheimer's disease this year.
A study led by Helena Jernberg Wiklund, Uppsala University / SciLifeLab, shows how the protein EZH2 affects the
development of multiple myeloma, and that inhibition of EZH2 could be used as a new strategy to treat the disease.
THE PATIENT AS INNOVATOR With Deborah Brooks of The Michael J. Fox Foundation for Parkinson's Research; Kathy
Giusti of the Multiple Myeloma Research Foundation & Consortium; Sean Lane of Crosschx; Claudia Williams of the White House Office of Science and Technology Policy; Rik Kirkland, of McKinsey & Co. — Report by Kia Kokalitcheva — Video: Patients Should Get Access to Their Health Data
While the cause of MGUS and multiple myeloma (plasma cell cancer) remains largely unclear, studies have reported an elevated
risk of multiple myeloma among farmers and other agricultural workers and pesticides have been thought to be the basis for these associations, according to study background.
A first - in - human Phase I
study of multiple myeloma patients combined expanded cord blood - derived natural killer cells with transplantation of a patient's own stem cells and high - dose chemotherapy with little or none of the side effects seen with current treatments.
«Our group, which includes more than 180 myeloma researchers worldwide, has updated the definition
of multiple myeloma for diagnostic purposes to include validated biomarkers in addition to the current clinical symptoms used for diagnosis which include, elevated blood calcium levels, kidney failure, anemia and bone lesions,» said lead author S. Vincent Rajkumar, M.D. a hematologist at Mayo Clinic.
December 6, 2011 Drug combination highly effective for newly diagnosed myeloma patients, study finds A three - drug combination treatment for the blood cancer multiple myeloma compares favorably to the best established therapy for newly diagnosed patients, according to a multi-center study led by Andrzej Jakubowiak, MD, PhD, professor of medicine and director
of the multiple myeloma program at the University of Chicago Medical Center.
The
mission of the Multiple Myeloma Research Foundation (MMRF) is to accelerate next generation multiple myeloma treatments to extend patients» lives in pursuit of a cure.
Using a
database of multiple myeloma patient samples and information, researchers at University of California San Diego School of Medicine found that high ADAR1 levels correlate with reduced survival rates.
In our study, as BMI increased, we started seeing an increase in the
ability of multiple myeloma cells to adhere, which causes the cancer to better anchor,» DeCicco - Skinner explained.
«In the future, we will look at whether healthy weight loss is inversely associated with the
progression of multiple myeloma in MGUS patients or how weight change plays a role in the progression of MGUS to multiple myeloma,» Chang said.
Half of multiple myeloma patients diagnosed in the earliest stage of the disease don't survive beyond about five years after initial treatment because the cancer becomes resistant to treatments.
«Sustained
remission of multiple myeloma after personalized cellular therapy: New treatment combination with CTL019 targets precursors of cancerous white blood cells.»
Bradner and Mitsiades had reported in Cell in 2011 that the inhibitor blocks the Myc cancer gene and thereby slows the
growth of multiple myeloma tumors in mice.
Follin - Arbelet V, Torgersen ML, Naderi EH, Misund K, Sundan A, Blomhoff HK
Death of multiple myeloma cells induced by cAMP - signaling involves downregulation of Mcl - 1 via the JAK / STAT pathway Cancer Lett (in press) PubMed 23454584
He was the founding
Chairman of the Multiple Myeloma Research Consortium, Clinical Trials Core and now chairs the Multiple Myeloma Committee for the Alliance for Clinical Trials in Oncology (the former CALGB).
KLF9 - Novel Transcriptional
Regulator of Multiple Myeloma Chemotherapy Resistance Multiple myeloma (MM) is a plasma cell disorder that accounts for approximately 10 % of all hematologic malignancies.
A common
effect of multiple myeloma is osteoporosis, and as a consequence patients develop intense back pain as their vertebrae become compressed as well as bone fractures.
With this combination of natural food protocols, Cellect and the antibody treatment I have seen a dramatic reduction in my cancer marker (a blood test result which measures a protein like cell which is an
indicator of multiple myeloma activity).
The implication of NETs in myeloma progression and targeting a process of NET formation for
treatment of multiple myeloma are under investigation.
The American Cancer Society estimates that 30,330 new
cases of multiple myeloma will occur in the United States in 2016 and about 12,600 people will die from it.
Elusive Cancer Stem Cell Identified Johns Hopkins Kimmel Cancer Center scientists have identified the cell likely to be responsible for the
development of multiple myeloma, a cancer of the bone marrow that destroys bone tissue.
Being overweight or obese has been known to increase the
risk of multiple myeloma, a cancer of the plasma cells in the blood and bone marrow that develops more often after age 60.